Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing.
Charlotte L B M KorstKazimierz GroenPatricia W C BosmanFleur van der ValkChristie P M VerkleijSandy KruyswijkMaaike E M de RuijterDianne M HeijinkMaria T KuipersSonja ZweegmanNiels W C J van de DonkPublished in: HemaSphere (2024)